Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

Clinical and genetic features of primary hemophagocytic lymphohistiocytosis: A single-center analysis

Yu Li, Jingshi Wang, Zhao Wang

Blood (2025) 146 (Supplement 1): 1219.

https://doi.org/10.1182/blood-2025-1219

Published: 2025

Journal Articles

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Blood (2025) 146 (Supplement 1): 88.

https://doi.org/10.1182/blood-2025-88

Published: 2025

Journal Articles

Clinical outcomes following single unrelated cord blood transplantation with ATG conditioning regimen for the treatment of mucopolysaccharidosis

Feng Shunqiao, Rong Liu, Zhao Wang

Blood (2025) 146 (Supplement 1): 2422.

https://doi.org/10.1182/blood-2025-2422

Published: 2025

Journal Articles

Anakinra for hemophagocytic lymphohistiocytosis: A real-world, multicenter retrospective study on efficacy, safety, and response durability

Lin Wu, Jingshi Wang, Na Wei, Zhao Wang

Blood (2025) 146 (Supplement 1): 6573.

https://doi.org/10.1182/blood-2025-6573

Published: 2025

Journal Articles

Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study

Huang He, Qingqing Cai, Yi Xia, Yirong Jiang, Zhao Wang, Yu Wang, Xiaojie Fang, Lulu Zhang, Jiahao Tian

Blood (2025) 146 (Supplement 1): 5363.

https://doi.org/10.1182/blood-2025-5363

Published: 2025

Journal Articles

Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Zheng Song, Ying Cheng, Haiyan Yang, Liling Zhang, Liqun Zou, Ye Guo, Junning Cao, Huiqiang Huang, Zhao Wang, Sha Huang, Yiqian Fang, Jiaoyan Lyu, Keshu Zhou, Huilai Zhang

Blood (2024) 144 (Supplement 1): 986.

https://doi.org/10.1182/blood-2024-193167

Published: 2024

Journal Articles

Development of ThisCART371 Targeting CLL1 for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Xiaomei Zhang, Xia Xiao, Hairong Lv, Xue Bai, Pengjiang Liu, Yedi Pu, Juanxia Meng, Haibo Zhu, Zhao Wang, Huan Zhang, Xiaoyuan He, Yu Zhang, Cuicui Lv, Yifan Zhao, Shujing Guo, Jile Liu, Mohan Zhao, Jun Li, Mingfeng Zhao

Blood (2024) 144 (Supplement 1): 7210.

https://doi.org/10.1182/blood-2024-204381

Published: 2024

Journal Articles

Rovadicitinib in Patients with Hemophagocytic Lymphohistiocytosis: A Single Arm, Open-Label, Phase I Study

Zhao Wang, Jingshi Wang, Lin Wu, Deli Song, Yubo Pi, Dawei Ding, Yao Chen, Xunqiang Wang

Blood (2024) 144 (Supplement 1): 806.

https://doi.org/10.1182/blood-2024-203214

Published: 2024

Journal Articles

Updated Outcome from Biomarker MSC-C5b-9-Guided All-Trans Retinoic Acid Treatment for Resistant/Recurrent ITP: A Multicenter, Randomized, Open-Label, Phase 3 Clinical Trial

Menglin Li, HaiXia Fu, Hui Liu, Ru Feng, Yi Liu, Jingwen Wang, Lei Yang, Zhao Wang, Gaochao Zhang, Qingyuan Qu, Yuxiu Chen, Jianying Zhou, Mengyu Xiao, Lulu Wang, Mengtong Zang, Yun He, Xiaolu Zhu, Xiaosu Zhao, Xiaohui Zhang

Blood (2024) 144 (Supplement 1): 712.

https://doi.org/10.1182/blood-2024-198335

Published: 2024

Journal Articles

Zanubrutinib As Salvage Therapy for Refractory/Relapsed Hemophagocytic Lymphohistiocytosis in Adults: A Single Center, Prospective Study

Jingshi Wang, Deli Song, Lin Wu, Na Wei, Yubo Pi, Zhao Wang

Blood (2024) 144 (Supplement 1): 5381.

https://doi.org/10.1182/blood-2024-210260

Published: 2024

Journal Articles

CXCL-9 and IL-18: Potential Biomarkers for Efficacy Evaluation in Refractory Hemophagocytic Lymphohistiocytosis Treated with RED (Ruxolitinib, Emapalumab and Dexamethasone)

Xuan Lan, Zhao Wang

Blood (2024) 144 (Supplement 1): 5380.

https://doi.org/10.1182/blood-2024-210196

Published: 2024

Journal Articles

Chronic active Epstein-Barr virus disease originates from infected hematopoietic stem cells

Jingshi Wang, Min Su, Na Wei, Huanyu Yan, Jia Zhang, Yi Gong, Lin Wu, Dina Suolitiken, Yubo Pi, Deli Song, Leilei Chen, Huan Liu, Shuo Yang, Xi Wang, Zhao Wang

Blood (2024) 143 (1): 32–41.

https://doi.org/10.1182/blood.2023021074

Published: 2024

Includes: Supplemental data

Journal Articles

Biomarker MSC-C5b-9-Guided Master Therapies for Resistant/Recurrent ITP: A Prospective, Randomized, Open-Label, Multicenter Trial

Menglin Li, Haixia Fu, Yi Liu, Hui Liu, Ru Feng, Zhao Wang, Jingwen Wang, Yuxiu Chen, Qingyuan Qu, Mengyu Xiao, Jianying Zhou, Yun He, Xiaolu Zhu, Yuan Kong, Yingjun Chang, Kaiyan Liu, Xiaohui Zhang

Blood (2023) 142 (Supplement 1): 3951.

https://doi.org/10.1182/blood-2023-182669

Published: 2023

Journal Articles

A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Jun Zhu, Yuqin Song, Ye Guo, Keshu Zhou, Wenyu Li, Yu Yang, Qingqing Cai, Zhao Wang, Haiyan Yang

Blood (2023) 142 (Supplement 1): 3089.

https://doi.org/10.1182/blood-2023-189675

Published: 2023

Journal Articles

Caebv Disease Originates from Infected Hematopoietic Stem Cells

Jingshi Wang, Na Wei, Jia Zhang, Lin Wu, Xi Wang, Zhao Wang

Blood (2023) 142 (Supplement 1): 1175.

https://doi.org/10.1182/blood-2023-173226

Published: 2023

Journal Articles

Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society

Blood (2023) 142 (Supplement 1): 2537.

https://doi.org/10.1182/blood-2023-188829

Published: 2023

Journal Articles

A Phase I Clinical Trial of CLL-1 CAR-T Cells for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia in Adults

Blood (2023) 142 (Supplement 1): 2106.

https://doi.org/10.1182/blood-2023-180387

Published: 2023

Journal Articles

Baricitinib in Combination with High-Dose Dexamethasone As First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia: A Prospective, Multicenter, Randomized Trial

Blood (2023) 142 (Supplement 1): 1207.

https://doi.org/10.1182/blood-2023-181622

Published: 2023

Journal Articles

The Combination of Iguratimod and Danazol Versus Danazol As a Treatment of Corticosteroid-Resistant/Relapse Immune Thrombocytopenia: A Randomized, Controlled, Multicenter, Open-Label Trial

Xiaolu Zhu, Hui Liu, Zhao Wang, Zhongxing Jiang, Liangming Ma, Min Wang, Jiamin Zhang, Zhuoyu An, Yejun Wu, Yun He, Haixia Fu, Yingjun Chang, Lanping Xu, Kaiyan Liu, Xiao Jun Huang, Xiaohui Zhang

Blood (2023) 142 (Supplement 1): 2589.

https://doi.org/10.1182/blood-2023-184342

Published: 2023

Journal Articles

Prophylactic or Preemptive Donor-Derived CD19 CAR-T Cell Infusion for Preventing Relapse in High-Risk B-ALL after Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 2100.

https://doi.org/10.1182/blood-2023-173926

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Clinical and genetic features of primary hemophagocytic lymphohistiocytosis: A single-center analysis

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Clinical outcomes following single unrelated cord blood transplantation with ATG conditioning regimen for the treatment of mucopolysaccharidosis

Anakinra for hemophagocytic lymphohistiocytosis: A real-world, multicenter retrospective study on efficacy, safety, and response durability

Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study

Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Development of ThisCART371 Targeting CLL1 for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Rovadicitinib in Patients with Hemophagocytic Lymphohistiocytosis: A Single Arm, Open-Label, Phase I Study

Updated Outcome from Biomarker MSC-C5b-9-Guided All-Trans Retinoic Acid Treatment for Resistant/Recurrent ITP: A Multicenter, Randomized, Open-Label, Phase 3 Clinical Trial

Zanubrutinib As Salvage Therapy for Refractory/Relapsed Hemophagocytic Lymphohistiocytosis in Adults: A Single Center, Prospective Study

CXCL-9 and IL-18: Potential Biomarkers for Efficacy Evaluation in Refractory Hemophagocytic Lymphohistiocytosis Treated with RED (Ruxolitinib, Emapalumab and Dexamethasone)

Chronic active Epstein-Barr virus disease originates from infected hematopoietic stem cells

Biomarker MSC-C5b-9-Guided Master Therapies for Resistant/Recurrent ITP: A Prospective, Randomized, Open-Label, Multicenter Trial

A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Caebv Disease Originates from Infected Hematopoietic Stem Cells

Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society

A Phase I Clinical Trial of CLL-1 CAR-T Cells for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia in Adults

Baricitinib in Combination with High-Dose Dexamethasone As First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia: A Prospective, Multicenter, Randomized Trial

The Combination of Iguratimod and Danazol Versus Danazol As a Treatment of Corticosteroid-Resistant/Relapse Immune Thrombocytopenia: A Randomized, Controlled, Multicenter, Open-Label Trial

Prophylactic or Preemptive Donor-Derived CD19 CAR-T Cell Infusion for Preventing Relapse in High-Risk B-ALL after Allogeneic Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only